子宫内膜异位症患者血清CA125测定

子宫内膜异位症患者血清ＣＡ＿（１２５）测定熊晓燕，舒明炎，高晓秋，刘惠兰，丛克家目前，子宫内膜异位症的诊断，主要依靠临床症状、体征及腹腔镜所见，而缺乏特异性手段。近年来研究发现，子宫内膜异位症患者血清ＣＡ＿（１２５）升高￣［１］。本研究对１１６例开腹...     

不同部位子宫内膜异位症与血清CA125水平的关系

目的:探讨血清CA125水平与不同部位的子宫内膜异位症之间的相关性。方法:选择经手术或腹腔镜确诊的内异症患者63例和排除内异症的对照组30例,按内异症发生部位的不同分为3组:Ⅰ组(卵巢内异组)34例;Ⅱ组(阴道直肠隔内异组)15例;Ⅲ组(腹壁切口内异组)14例。Ⅳ组为对照组,系临床和病理检查排除了内异症的健康者。术前采取空腹静脉血,用化学发光法测定各组血清中CA125水平。结果:(1)卵巢内异组、阴道直肠内异组的血清CA125水平均显著高于对照组(P<0·05);腹壁切口内异组CA125水平显著低于卵巢内异组(P<0·05),而与阴道直肠隔内异症组、对照组比较无统计学差异(P>0·05);(2)以血清CA125≥35U/ml为临界值,CA125诊断各组内异症的敏感性分别为:卵巢内异症52·94%,阴道直肠内异症40·00%,腹壁切口内异症21·43%。诊断特异性为96·67%。结论:CA125在诊断子宫内膜异位症发生方面具有一定的价值,但并不是敏感指标。单凭血清CA125不能鉴别不同部位的子宫内异症。     

血清CA125与抗子宫内膜抗体联合测定对子宫内膜异位症的诊断价值

目的 探讨血清CA125与抗子宫内膜抗体联合测定对于宫内膜异位症诊断的临床价值。方法 应用放射免疫法及酶联免疫吸附试验（ELISA）法测定44例子宫内膜异位症患者（EMT组）血清中CA125值及EMAb阳性情况，并与40例健康妇女对照组进行比较。结果 EMT组血清CA125值阳性率为61．4％（27／44），显著高于对照组5．0％（2／40），P〈0．05；EMT组抗子宫内膜抗体阳性率为65．9％（29／44），显著高于对照组7．5％（3／40），P〈0．05；联合测定EMT患者血清CA125值及抗子宫内膜抗体，其敏感性明显高于两者单独测定的敏感性。结论 血清CA125与抗子宫内膜抗体联合测定可提高子宫内膜异位症诊断的敏感性。     

联合测定血清EMAb和CA125对子宫内膜异位症的诊断价值

子宫内膜异位症 (ｅｎｄｏｍｅｔｒｉｏｓｉｓ ,ＥＭＴ)多见于生育期妇女 ,是引起下腹部疼痛的主要原因之一 ,其发病率各家报道不一 ,变化于 1%～ 5 0 %之间[1] 。腹腔镜是目前诊断ＥＭＴ的金标准 ,至今尚无一种简单有效的非损伤性的诊断方法 ,本文通过联合测定血清抗子宫内膜抗体 (ＥＭＡｂ)和ＣＡ12 5水平 ,以期为ＥＭＴ诊断提供一条新途径。1　资料与方法1 1　研究对象ＥＭＴ患者 34例 (ＥＭＴ组 ) ,年龄 2 1～ 4 6岁 ,平均为33 6岁 ,均为 1999年 11月至 2 0 0 1年 1月在我院妇科经手术病理诊断为ＥＭＴ住院患者。按修订的美国生育学会(…     

子宫内膜异位症患者血清中抗子宫内膜IgG抗体及CA125的测定

子宫内膜异位症 (内异症 )近年已成为一种严重影响育龄妇女生存质量的常见病。腹腔镜可早期诊断 ,但它是一种创伤性操作 ,费用高。为寻求简便、易行、无创性诊断方法 ,我们对内异症患者、正常及良性疾病对照者血清中的抗子宫内膜ＩｇＧ抗体及ＣＡ12 5值进行了测定 ,并探讨其用于临床诊断内异症的意义。一、资料和方法1.研究对象 :为 1998年 8月至 1999年 10月在我院住院经腹腔镜和开腹手术及病理检查证实为内异症的 39例患者 ,按 1985年美国生育协会修正的内异症分期法 (ＲＡＦＳ)进行分期 ,Ⅰ、Ⅱ期 8例 ,Ⅲ期 16例 ,Ⅳ期 15例 ;对照组 5 2…     

子宫内膜异位症患者血清CA125,抗子宫内膜抗体的测定

子宫内膜异位症患者血清ＣＡ１２５、抗子宫内膜抗体的测定伍俊萍张惜阴子宫内膜异位症是生育年龄妇女的常见病，我们测定子宫内膜异位症患者血清ＣＡ１２５、抗子宫内膜抗体（ＥｍＡｂ）的水平，并探讨其诊断价值。一、资料与方法１．研究对象：从我院１９９３年１２月至...     

联合测定子宫内膜异位症患者血清中EMAb及CA125的临床评价

目的：对联合测定子宫内膜异位症（内异症）患者血清中ＥＭＡｂ及ＣＡ１２５进行临床评价。方法：采取内异症１０９例术前（内异症组）和健康妇女３０例（对照组）空腹静脉血，用酶联免疫吸附法（ＥＬＩＳＡ）测定两组血清中ＥＭＡｂ水平；用放射免疫法（ＲＩＡ）测定血清中ＣＡ１２５水平。结果：内异症组ＥＭＡｂ阳性率为６３．３０％，对照组为１０％，两组差异有显著性（Ｐ＜０．０５）。内异症各期及子宫腺肌病间ＥＭＡｂ阳性率差异无显著性（Ｐ＞０．０５）。内异症组血清ＣＡ１２５水平平均为７０．７０±１６．６２Ｕ／ｍｌ，对照组为１５．３８±５．３２Ｕ／ｍｌ，两组差异有显著性。如以ＣＡ１２５≥３５Ｕ／ｍｌ为阳性界值，则内异症组阳性率为８０．２３％，对照组为６．６６％。单独测定ＥＭＡｂ诊断内异症的敏感性为６３．３０％，特异性为９０％；单独测定ＣＡ１２５诊断内异症的敏感性为８０．２３％、特异性为９３．３３％。如以两者均阳性为诊断标准，则敏感性为５７．８０％，特异性为１００％；如以其中之一阳性为诊断标准，则敏感性为９１．７４％，特异性为８３．３３％。结论：测定内异症患者血清中ＥＭＡｂ及ＣＡ１２５水平对内异症有较好的辅助诊断价值，联合测定ＥＭＡｂ及?     

CA125与子宫内膜抗体测定用于诊断子宫内膜异位症

测定了４２例妇女血清和腹腔液ＣＡ＿（１２５）及子宫内膜抗体（ＥＭＡｂ）水平，其中经腹腔镜诊断为子宫内膜异位症者２８例（观察组），无子宫内膜异位症者１４例（对照组）。结果表明：观察组血清ＥＭＡｂ的吸光度为０．４４±０．１３，明显高于对照组的０．３４±０．０７，但两组间血清ＣＡ＿（１２５）差异无显著性；两含用于诊断的敏感性分别为７１．４３％和８２．１４％，特异性为５７．２１％和５７．１４％。两组腹腔液中ＥＭＡｂ差异无显著性；两组腹腔液ＣＡ＿（１２５）和ＥＭＡｂ水平均明显高于血清。     

CA125与子宫内膜异位症的关系

ＣＡ１２５是一种血清抗原，普遍认为是上皮性卵巢癌的肿瘤标志物，８０年代中后期发现它与子人膜异位症也密切相关。子宫内膜异位病患者血清ＣＡ１２５水平较正常妇女高，在Ⅲ－Ⅳ期患者差异更大。对诊断子宫内膜异位症有一定价值。     

CA—125与子宫内膜异位症

CA～125是一种糖蛋白抗原,许多学者发现在子宫内膜异位症患者的血清及腹腔液中此抗原水平升高,并对 CA-125在子宫内膜中的分布情况,CA-125与子宫内膜异位症的关系及其在子宫内膜异位症的诊断,治疗效果的评价和复发的监测等方面的应用进行了广泛的研究。     

High concentrations of the CA-125, CA 19-9 and CA 15-3 in the peritoneal fluid between patients with and without endometriosis

Objective In the present study we compared the levels of CA-125, CA 19-9, and CA 15-3 in the peritoneal fluid (PF) of patients with and without endometriosis, then assessed the possibility of a correlation among these tumor markers.Study design Our study was a controlled clinical study of patients undergoing laparoscopy for infertility or other benign gynecology conditions. Peritoneal fluid samples were collected from 65 women with endometriosis and 43 women without pelvic disease. Levels of CA-125, CA 19-9 and CA 15-3 in the peritoneal fluid were determined by immunoradiometric assay.Results The concentration of CA-125 in PF from patients with endometriosis was significantly higher than that in the control group (p<0.001); for CA 19-9 and CA 15-3, PF concentrations were not statistically different between these two groups. Women with endometriosis had significantly higher levels of CA-125 in proliferative and secretory phases than the control group (p<0.001 and p<0.002 respectively); furthermore, in patients with endometriosis the CA 19-9 levels were significantly lower in secretory phase than the proliferative (p<0.004). The levels of CA-125 were significantly lower in women with tubal ligation, in comparison with infertility or pelvic pain in the control group (p<0.001). No significant difference was seen in women with infertility or pelvic pain in endometriosis group and the levels of CA-125, CA 19-9, and CA 15-3. We did not find any correlation between the stages of endometriosis and the concentration of CA-125, CA 19-9 and CA 15-3. A significant correlation between the CA 19-9 levels and CA 15-3 in patients with endometriosis was found (r=0.72, p=0.001).Conclusions We found high concentrations of CA-125, CA 19-9, and CA 15-3 in the peritoneal fluid of women with and without endometriosis in the Yale series. However, the levels only of CA-125 were higher in women with endometriosis, but without diagnostic value. The role of simultaneously high concentrations of CA 19-9 and CA 15-3 in women with endometriosis needs to be explored further.     

Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis

OBJECTIVE: To investigate the clinical value of the serum CA19-9 level in comparison with the serum CA125 level for diagnosing and determining the severity of endometriosis. DESIGN: Retrospective study. SETTING: Department of Comprehensive Reproductive Medicine in a university hospital. PATIENT(S): One hundred one women with endometriosis and 22 without endometriosis participated in this study. INTERVENTION(S): Blood samples were collected before the operation (laparoscopy, oophrectomy, cystectomy, and/or hysterectomy), and tissue samples of ovarian chocolate cysts were collected during the operation. MAIN OUTCOME MEASURE(S): The serum CA19-9 and CA125 levels and the localization of these antigens in ovarian chocolate cysts. RESULT(S): The mean serum CA19-9 levels in patients at all stages of endometriosis were significantly higher than those in patients without endometriosis, and serum CA19-9 levels significantly correlated with the Revised American Fertility Society classification scores. Intense staining of CA19-9 was observed in 15 of the 20 samples of ovarian chocolate cysts. CONCLUSION(S): CA19-9 is a useful marker for determining the severity of endometriosis.     

CA19-9, CA125 and CEA in endometrial carcinoma tissue and its relation to hormone receptor content and histological grading

Summary Samples of 40 endometrial carcinomas were examined by immunohistochemical methods for CA19-9, CA125 and CEA. CA19-9 was detected in 93%, CA125 in 65% and CEA in 58%. CA19-9 was detected in more than 50% of tumor cells in 14 cases and the same was true for CA125 in six cases. In no tumor was CEA found in more than half the cells. The distribution of CA125 and CEA was markedly more heterogenous than that of CA19-9. There was no statistically significant correlation between immunohistochemical markers on the one hand, and estrogen and progesterone receptor content on the other. A correlation between histological grading and marker detection was only found for CA19-9. CA19-9 was detected in almost all endometrial carcinoma samples, and was the most homogenously distributed. This makes CA19-9 a possibly useful tumor marker for endometrial carcinoma.     

Dolor abdominal agudo secundario a endometrioma ovárico roto con elevación de CA 125 y CA 19 - 9

A 47-year-old woman presented to the emergency department complaining of abdominal pain for the last 3 days, with an increase in serum levels of white blood cells, CA19-9 and CA-125. Surgery revealed a ruptured left ovarian endometrioma. In this case, high levels of both antigens forced us to exclude an ovarian neoplasm.     

卵巢肿瘤患者血清CA19—9水平升高的临床意义

目的探讨血清CA19-9水平在卵巢肿瘤中的升高情况及临床意义。方法回顾性分析首都医科大学附属北京友谊医院2007年1月至2008年12月间收治的377例卵巢肿瘤患者的血清CA19-9水平及相关的临床资料。结果377例患者中,血清CA19-9水平升高者89例,阳性率23．6％0。主要见于成熟畸胎瘤、卵巢子宫内膜异位囊肿、交界性肿瘤及恶性肿瘤患者,其阳性率分别为27．3％、31．7％、42．9％和28．1％,高于良性肿瘤（19．3％）、卵巢瘤样病变（23．9％）和卵巢转移癌（12．5％）,但差异无统计学意义（P〉O．05）;双侧卵巢成熟畸胎瘤的阳性率为53．3％,高于单侧（19．6％）,差异无统计学意义（P〉O．05）。CA19-9检测卵巢恶性肿瘤的特异度为76．6％,灵敏度为25％,与CAl25联合其灵敏度和特异度分别为82．5％和59．1％。结论CA19-9对卵巢畸胎瘤和子宫内膜异位囊肿的诊断有一定的参考价值,与CA125联用可提高卵巢恶性肿瘤的检出率。     

Heavy black tea consumption and elevated CA 19-9 and CA 125 levels. A case report on a patient with ovarian endometriotic cysts

Abstract

In this case report, we present a case of false positive CA 19-9 and CA 125 levels in a patient with suspected endometriotic cysts. The patient is a 34-year-old nulliparous woman with heavy black tea consumption and elevated CA 19-9 and CA 125 levels. After discontinuation of black tea intake and careful exploration of other possible factors, CA 19-9 and CA 125 levels dropped markedly. As a conclusion, heavy black tea consumption can lead to false positive results of elevated CA 19-9 and CA 125 levels.     

CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的比较

目的:探讨血清糖类抗原125(CA125)及CA125联合CA199、CA153、癌胚抗原(CEA)检测在卵巢癌诊断中的意义。方法:采用化学发光微粒子免疫检测法测定71例卵巢癌患者、10例卵巢交界性肿瘤患者和42例卵巢良性肿瘤患者血清中CA125、CA199、CA153和CEA的含量,阳性诊断标准分别为:CA12535 k U/L,CA19937 k U/L,CA15330 k U/L,CEA5μg/L。结果:在单项肿瘤标记物中,CA125的阳性率最高(84.5%),敏感度、特异度和准确度指标平稳。在不同的联合检测方案中CA199、CA153与CA125联合检测方案最优,较CA125单项检测敏感度和准确度均有提高。晚期卵巢癌(Ⅲ~Ⅳ期)患者的CA153、CA125含量高于早期卵巢癌(Ⅰ~Ⅱ期)患者(P0.001)。结论:CA199、CA153、CEA与CA125在卵巢癌鉴别诊断中均有一定价值,并可以根据CA153、CA125含量判断患者卵巢癌的分期,CA199、CA153与CA125联合检测是诊断卵巢癌较为理想的标记物组合。     

Imperforate hymen: a new benign reason for highly elevated serum CA 19.9 and CA 125 levels

Absract Imperforate hymen is a urogenital tract anomaly that represents the most frequent congenital malformation of the female genital tract. CA 19-9 and CA 125 are widely used as tumor markers, however several benign conditions are also known to increase serum CA 19-9 and CA 125 levels. According to classical textbook knowledge, imperforate hymen is not listed under the benign conditions that increase serum CA 19-9 and CA 125 levels. In this case report we describe a relation between imperforate hymen and elevated serum CA 19-9 and CA 125 levels.     

CA19-9、CA125和CP2在卵巢黏液性肿瘤诊断和监测中的价值

目的探讨血清肿瘤标志物CA19-9、CA125及CP2在卵巢黏液性肿瘤诊断和监测中的价值。方法对北京大学人民医院1999年1月至2007年6月间收治的273例卵巢肿瘤患者的临床资料进行回顾性分析,探讨血清肿瘤标志物CA19-9、CA125及CP2在50例卵巢黏液性肿瘤诊断和监测中的价值,并与223例卵巢非黏液性肿瘤进行比较。结果（1）卵巢黏液性肿瘤中,CA19-9的曲线下面积最大（为0．95）,其次是CA125（为0．90）;而卵巢非黏液肿瘤中,CA125和CP2的曲线下面积最大（均为0．90）。（2）卵巢黏液性肿瘤患者联合检测CA19-9和CA125时,其敏感度（93．8％）较单项检测（CA19-9和CA125分别为75．0％和66．7％）明显提高（P〈0．05）,而特异度（分别为86．1％、86．6％和90．2％）无明显变化（P〉0．05）。卵巢非黏液性肿瘤患者联合检测CA125和CP2时的敏感度（85．0％）,较CP2（70．6％）单项检测明显提高,差异有统计学意义（P〈0．05）;较CA125（80．7％）单项检测虽有提高,但差异无统计学意义（P〉0．05）;3者的特异度（分别为90．2％、88．5％和93．9％）比较,差异无统计学意义（P〉0．05）。（3）82例卵巢恶性肿瘤术前血清肿瘤标志物阳性患者中。可行满意的肿瘤细胞减灭术患者[70％（57／82）]的血清肿瘤标志物于术后2个月内降为正常的百分率高于未能行满意肿瘤细胞减灭术者（分别为75％和28％）,差异有统计学意义（P〈0．05）;且其术后血清肿瘤标志物再次上升的平均时间延长（分别为18．2和16．4个月）,但差异无统计学意义（P〉0．05）;复发率（分别为35％和56％）及死亡率（分别为14％和32％）降低,差异有统计学意义（P〈0．05）。20例术前血清肿瘤标志物阴性患者均可行满意的肿瘤细胞减灭术,其中复发患者仅2例（10％）。（4）卵巢黏液性肿瘤患者术后复发时多为血清CA19-9水平上升,而卵巢非黏液性肿瘤术后复发时主要为血清CA125水平上升,部分患者血清CP2水平也上升。（5）术前血清肿瘤标志物阳性患者较阴性患者生存率明显下降,其中CA125（＋）与CA125（-）、CP2（＋）与CP2（-）患者间生存率比较,差异有统计学意义（P〈0．05）;而CA19-9（＋）与CA19-9（-）患者间生存率比较,差异则无统计学意义（P〉0．05）。结论CA19-9是诊断卵巢黏液性肿瘤的敏感指标,与CA125联合检测可提高对卵巢黏液性肿瘤诊断的敏感度,并对术后监测有重要临床意义。CA125和CP2联合检测则对诊断卵巢非黏液肿瘤更敏感。     

超声联合CA125对卵巢恶性肿瘤的诊断价值

目的：探讨超声和肿瘤免疫标记物CA_(125)联合诊断卵巢恶性肿瘤的价值。方法：对139例卵巢肿瘤患者,其中恶性45例,良性94例,分别经腹及经阴道超声观察二维图像,并进行彩色及频谱多普勒检查,记录阻力指数。同时用放射免疫法测定患者血清CA_(125)。分别对卵巢肿瘤进行良恶性的判定,并与术后病理进行对照。结果：二维超声及肿瘤标记物CA_(125)联合应用诊断卵巢恶性肿瘤的敏感性及特异性高于单独的任何一种方法。结论：二维超声及肿瘤标记物CA_(125)联合应用对诊断卵巢恶性肿瘤有一定的价值。